Biodexa Pharmaceuticals (BDRX) Competitors

Esperion Therapeutics (NASDAQ:ESPR) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings.

Does the MarketBeat Community favor ESPR or BDRX?

Esperion Therapeutics received 626 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 70.21% of users gave Esperion Therapeutics an outperform vote.

Company	Underperform	Outperform
Esperion Therapeutics	Outperform Votes 627 70.21%	Underperform Votes 266 29.79%
Biodexa Pharmaceuticals	Outperform Votes 1 100.00%	Underperform Votes No Votes

Do analysts rate ESPR or BDRX?

Esperion Therapeutics presently has a consensus price target of $6.75, indicating a potential upside of 305.41%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biodexa Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media prefer ESPR or BDRX?

In the previous week, Esperion Therapeutics had 7 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 9 mentions for Esperion Therapeutics and 2 mentions for Biodexa Pharmaceuticals. Esperion Therapeutics' average media sentiment score of 0.49 beat Biodexa Pharmaceuticals' score of 0.20 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodexa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, ESPR or BDRX?

Esperion Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of ESPR or BDRX?

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is ESPR or BDRX more profitable?

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	-29.37%	N/A	-10.77%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Which has stronger valuation & earnings, ESPR or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Esperion Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$332.31M	0.99	-$209.25M	-$0.25	-6.66
Biodexa Pharmaceuticals	$83K	713.27	-$7.66M	N/A	N/A

Summary

Esperion Therapeutics beats Biodexa Pharmaceuticals on 9 of the 15 factors compared between the two stocks.